2 Biotech Stocks You Can Buy and Hold for the Next Decade
Many investing trends and fads come and go, but the need for innovative medicines isn't one of them. Drugs, especially those that treat potentially life-threatening conditions, are always in demand. That's why companies that develop and market medicines can remain relevant and perform well for a long time, provided they continue innovating and discovering newer and better therapies.
Let's look at two biotech stocks that can do exactly that through the next decade while delivering solid returns to their shareholders: Sanofi (NASDAQ: SNY) and Gilead Sciences (NASDAQ: GILD).
The year was going relatively smoothly for Sanofi until it reported its third-quarter results during which it announced some important business moves. First, the French pharmaceutical giant will separate its consumer health business into a stand-alone, publicly traded corporation also headquartered in France. Second, Sanofi abandoned its 2025 operating margin goal of 32% due to increased investment in its pipeline.
Source Fool.com
